[{"id":"1789ed10-9198-45cc-9844-3702a65c391f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02527317","created_at":"2021-01-18T12:13:10.096Z","updated_at":"2024-07-02T16:37:14.035Z","phase":"","brief_title":"Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer","source_id_and_acronym":"NCT02527317","lead_sponsor":"Beaumont Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" EGFR positive • ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Lonquex (lipegfilgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 02/01/2018","study_completion_date":" 02/01/2018","last_update_posted":"2018-02-09"},{"id":"95fceabc-1256-4d62-bf5f-e851a7477adc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02488382","created_at":"2021-01-18T11:59:19.629Z","updated_at":"2024-07-02T16:37:17.059Z","phase":"Phase 1/2","brief_title":"Lonquek for Autologous Stem Cell Mobilization","source_id_and_acronym":"NCT02488382","lead_sponsor":"Sheba Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonquex (lipegfilgrastim)"],"overall_status":"Unknown status","enrollment":" Enrollment 24","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2017-10-17"}]